Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Symeonidis

Showing results (531-540 of 578) with videos related to

Pageof 58
Sort By:
Annals of Hematology|May 21, 2017
Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordanceLouise de Swart, Alex Smith, Marius MacKenzie, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Prognostication of the high-risk WM patientEfstathios Kastritis, Maria Gavriatopoulou, Marie-Christine Kyrtsonis, et al.
Haematologica|January 26, 2006
Pure infradiaphragmatic Hodgkin's lymphoma. Clinical features, prognostic factor and comparison with supradiaphragmatic diseaseTheodoros P Vassilakopoulos, Maria K Angelopoulou, Marina P Siakantaris, et al.
Blood|August 28, 2013
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNetLuca Malcovati, Eva Hellström-Lindberg, David Bowen, et al.
American Journal of Hematology|April 22, 2011
No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 yearsEfstathios Kastritis, Marie-Christine Kyrtsonis, Evdoxia Hatjiharissi, et al.
British Journal of Haematology|May 6, 2025
Real-life experience of luspatercept in transfusion-dependent lower risk myelodysplastic syndrome patientsAnthi Bouchla, Sotirios G Papageorgiou, Ioannis Kotsianidis, et al.
Haematologica|November 11, 2017
Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromesLouise de Swart, Chloé Reiniers, Timothy Bagguley, et al.
Journal of Hepatology|March 4, 2023
Interferon-induced IL-10 drives systemic T-cell dysfunction during chronic liver injuryCarl-Philipp Hackstein, Jasper Spitzer, Konstantinos Symeonidis, et al.
Therapeutic Advances in Hematology|December 21, 2020
Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromesSotirios G Papageorgiou, Ioannis Kotsianidis, Anthi Bouchla, et al.
British Journal of Haematology|July 9, 2002
Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patientsEvangelos Terpos, Athina Mougiou, Alexandra Kouraklis, et al.
Pageof 58

Showing results (531-540 of 578) with videos related to

Sort By:
Pageof 58
Annals of Hematology|May 21, 2017
Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordanceLouise de Swart, Alex Smith, Marius MacKenzie, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Prognostication of the high-risk WM patientEfstathios Kastritis, Maria Gavriatopoulou, Marie-Christine Kyrtsonis, et al.
Haematologica|January 26, 2006
Pure infradiaphragmatic Hodgkin's lymphoma. Clinical features, prognostic factor and comparison with supradiaphragmatic diseaseTheodoros P Vassilakopoulos, Maria K Angelopoulou, Marina P Siakantaris, et al.
Blood|August 28, 2013
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNetLuca Malcovati, Eva Hellström-Lindberg, David Bowen, et al.
American Journal of Hematology|April 22, 2011
No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 yearsEfstathios Kastritis, Marie-Christine Kyrtsonis, Evdoxia Hatjiharissi, et al.
British Journal of Haematology|May 6, 2025
Real-life experience of luspatercept in transfusion-dependent lower risk myelodysplastic syndrome patientsAnthi Bouchla, Sotirios G Papageorgiou, Ioannis Kotsianidis, et al.
Haematologica|November 11, 2017
Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromesLouise de Swart, Chloé Reiniers, Timothy Bagguley, et al.
Journal of Hepatology|March 4, 2023
Interferon-induced IL-10 drives systemic T-cell dysfunction during chronic liver injuryCarl-Philipp Hackstein, Jasper Spitzer, Konstantinos Symeonidis, et al.
Therapeutic Advances in Hematology|December 21, 2020
Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromesSotirios G Papageorgiou, Ioannis Kotsianidis, Anthi Bouchla, et al.
British Journal of Haematology|July 9, 2002
Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patientsEvangelos Terpos, Athina Mougiou, Alexandra Kouraklis, et al.
Pageof 58